The European Commission and the EMA have published a roadmap for a European medicines agencies network strategy to address challenges posed by the COVID outbreak. The reform aims to ensure rapid access to high-quality medicines for all EU patients and equal access across member states. Delays in market availability of new medicines and unequal access are deemed unacceptable. The reform also targets specific health needs like rare diseases and antimicrobial resistance, considering the latter a significant future challenge. Tackling pricing issues of innovative medicines and positioning Europe as a global leader in medicine development are additional objectives. Digital transformation and assessing the environmental impact of medicines are key areas for improvement. These efforts align with European political objectives such as the green deal and the green economy.